Patents by Inventor Jaw-Kang Chang

Jaw-Kang Chang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210061893
    Abstract: Human phoenixin peptides, analogs and mimetics useful in production of anti-phoenixin antibodies, diagnostic screening and assays, and in modulating cellular concentration of cAMP, and treatment of disorders related to cAMP or Ca2+ concentration in cells, modulating hypertension and cardiovascular function, modulating gonadotrophs and gastric emptying.
    Type: Application
    Filed: November 4, 2020
    Publication date: March 4, 2021
    Applicant: Phoenix Pharmaceuticals, Inc.
    Inventors: Jaw-Kang Chang, Rong-Ming Lyu
  • Patent number: 10836812
    Abstract: Human phoenixin peptides, analogs and mimetics useful in production of anti-phoenixin antibodies, diagnostic screening and assays, and in modulating cellular concentration of cAMP, and treatment of disorders related to cAMP or Ca2+ concentration in cells, modulating hypertension and cardiovascular function, modulating gonadotrophs and gastric emptying.
    Type: Grant
    Filed: January 2, 2017
    Date of Patent: November 17, 2020
    Assignee: Phoenix Pharmaceuticals, Inc.
    Inventors: Jaw-Kang Chang, Rong-Ming Lyu
  • Publication number: 20170145083
    Abstract: Human phoenixin peptides, analogs and mimetics useful in production of anti-phoenixin antibodies, diagnostic screening and assays, and in modulating cellular concentration of cAMP, and treatment of disorders related to cAMP or Ca2+ concentration in cells, modulating hypertension and cardiovascular function, modulating gonadotrophs and gastric emptying.
    Type: Application
    Filed: January 2, 2017
    Publication date: May 25, 2017
    Applicant: Phoenix Pharmaceuticals, Inc.
    Inventors: Jaw-Kang Chang, Rong-Ming Lyu
  • Patent number: 9534045
    Abstract: Human phoenixin peptides, analogs and mimetics useful in production of anti-phoenixin antibodies, diagnostic screening and assays, and in modulating cellular concentration of cAMP, and treatment of disorders related to cAMP or Ca2+ concentration in cells, modulating hypertension and cardiovascular function, modulating gonadotrophs and gastric emptying.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: January 3, 2017
    Assignee: Phoenix Pharmaceuticals, Inc.
    Inventors: Jaw-Kang Chang, Rong-Ming Lyu
  • Publication number: 20150322141
    Abstract: Human phoenixin peptides, analogs and mimetics useful in production of anti-phoenixin antibodies, diagnostic screening and assays, and in modulating cellular concentration of cAMP, and treatment of disorders related to cAMP or Ca2+ concentration in cells, modulating hypertension and cardiovascular function, modulating gonadotrophs and gastric emptying.
    Type: Application
    Filed: April 27, 2015
    Publication date: November 12, 2015
    Applicant: Phoenix Pharmaceuticals, Inc.
    Inventors: Jaw-Kang Chang, Rong-Ming Lyu
  • Patent number: 9018350
    Abstract: Human phoenixin peptides, analogs and mimetics useful in production of anti-phoenixin antibodies, diagnostic screening and assays, and in modulating cellular concentration of cAMP, and treatment of disorders related to cAMP or Ca2+ concentration in cells, modulating hypertension and cardiovascular function, modulating gonadotrophs and gastric emptying.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: April 28, 2015
    Assignee: Phoenix Pharmaceuticals, Inc.
    Inventors: Jaw-Kang Chang, Rong-Ming Lyu
  • Publication number: 20140163202
    Abstract: Human phoenixin peptides, analogs and mimetics useful in production of anti-phoenixin antibodies, diagnostic screening and assays, and in modulating cellular concentration of cAMP, and treatment of disorders related to cAMP or Ca2+ concentration in cells, modulating hypertension and cardiovascular function, modulating gonadotrophs and gastric emptying.
    Type: Application
    Filed: May 25, 2012
    Publication date: June 12, 2014
    Applicant: Phoenix Pharmaceuticals, Inc.
    Inventors: Jaw-Kang Chang, Rong-Ming Lyu
  • Patent number: 7928186
    Abstract: Cell permeable bioactive peptide conjugates having a first bioactive peptide region coupled to a second transport peptide region allowing transfer of the first bioactive peptide region and the second transport peptide region across biological membranes to enter intact living cells for regulation of biological responses.
    Type: Grant
    Filed: August 2, 2007
    Date of Patent: April 19, 2011
    Assignee: Phoenix Pharmaceuticals, Inc.
    Inventor: Jaw-Kang Chang
  • Publication number: 20090030178
    Abstract: Cell permeable bioactive peptide conjugates having a first bioactive peptide region coupled to a second transport peptide region allowing transfer of the first bioactive peptide region and the second transport peptide region across biological membranes to enter intact living cells for regulation of biological responses.
    Type: Application
    Filed: August 2, 2007
    Publication date: January 29, 2009
    Inventor: Jaw-Kang Chang
  • Patent number: 7462355
    Abstract: Stable water soluble polypeptides which are potent inhibitors of endothelial cell proliferation and of angiogenesis. Polypeptide inhibitors of endothelial cell growth may have important uses in the elucidation of the mechanism of angiogenesis, disease diagnosis and prognostication, and drug therapies for use in animals and humans.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: December 9, 2008
    Inventor: Jaw-Kang Chang
  • Publication number: 20080124813
    Abstract: A method of small volume bead-based radioimmunoassay which includes utilization of an immunoassay particle having a solid phase substrate linked to a target particle capture moiety which dissociably captures target particles in an immunoassay sample. Specifically, a bead linked to antibody which competitively dissociably captures target particles and labeled particles of an immunoassay sample in a small volume bead-based radioimmunoassay to allow determination of the concentration of target particles, the level of protease activity, or the level of protease inhibitor activity in such immunoassay samples.
    Type: Application
    Filed: November 17, 2007
    Publication date: May 29, 2008
    Inventors: Jaw-Kang Chang, Rong Ming Lyu
  • Publication number: 20060275321
    Abstract: Compositions and methods of using such compositions to regulate biological responses associated with binding of HIV-1 polypeptides.
    Type: Application
    Filed: June 1, 2005
    Publication date: December 7, 2006
    Inventor: Jaw-Kang Chang
  • Patent number: 6953779
    Abstract: The clinical outcome of disseminated melanoma is grim. Small molecular weight antagonists (preferably about seven amino acid residues) specific for MCR on melanoma cells are provided for the therapy of melanoma as well as in other conditions where modulation of MCR is of clinical significance. A particularly preferred antagonist is p-anisoyl-[D-Arg6,9, D-Lys11, D-Leu12] dynorphin A(6-12)-NH2, which is an excellent antagonist of the MCR-1 receptor.
    Type: Grant
    Filed: May 4, 2001
    Date of Patent: October 11, 2005
    Inventors: Edward T. Wei, J. Mark Quillan, Wolfgang Sadée, Guennady P. Vlasov, Jaw Kang Chang
  • Publication number: 20050203015
    Abstract: Stable water soluble polypeptides which are potent inhibitors of endothelial cell proliferation and of angiogenesis. Polypeptide inhibitors of endothelial cell growth may have important uses in the elucidation of the mechanism of angiogenesis, disease diagnosis and prognostication, and drug therapies for use in animals and humans.
    Type: Application
    Filed: December 23, 2004
    Publication date: September 15, 2005
    Inventor: Jaw-Kang Chang
  • Patent number: 6835806
    Abstract: Stable water soluble polypeptides which are potent inhibitors of endothelial cell proliferation and of angiogenesis. Polypeptide inhibitors of endothelial cell growth may have important uses in the elucidation of the mechanism of angiogenesis, disease diagnosis and prognostication, and drug therapies for use in animals and humans.
    Type: Grant
    Filed: March 30, 2001
    Date of Patent: December 28, 2004
    Assignee: Phoenix Pharmaceuticals, Inc.
    Inventor: Jaw-Kang Chang
  • Publication number: 20020058620
    Abstract: Stable water soluble polypeptides which are potent inhibitors of endothelial cell proliferation and of angiogenesis. Polypeptide inhibitors of endothelial cell growth may have important uses in the elucidation of the mechanism of angiogenesis, disease diagnosis and prognostication, and drug therapies for use in animals and humans.
    Type: Application
    Filed: March 30, 2001
    Publication date: May 16, 2002
    Applicant: Phoenix Pharmaceuticals, Inc.
    Inventor: Jaw-Kang Chang
  • Patent number: 4721704
    Abstract: Biologically active atrial peptide analogs having 21 or 22 amino acid residues are provided with potent diuretic and natriuretic activities, and which lower blood pressure. These analogs have a .beta.-mercaptopropanoic acid derivative moiety at the N-terminus and have D-Alanine at the 3 position of the amino acid sequence.
    Type: Grant
    Filed: May 9, 1986
    Date of Patent: January 26, 1988
    Assignee: Peninsula Laboratories, Inc.
    Inventors: Jaw-Kang Chang, Ding Chang
  • Patent number: 4684624
    Abstract: A method of treatment for patients suffering from cerebral ischemia is provided by administering an opioid peptide. Particulary preferred is the administration of dynorphin, or dynorphin-related peptides, in the acid or amidated form. Practice of the invention is useful in prolonging survival.
    Type: Grant
    Filed: May 20, 1985
    Date of Patent: August 4, 1987
    Assignees: Yoshio Hosobuchi, Nancy M. Lee, Horace H. Loh, Jaw-Kang Chang
    Inventors: Yoshio Hosobuchi, Nancy M. Lee, Horace H. Loh, Jaw-Kang Chang
  • Patent number: 4613586
    Abstract: Novel peptides having gastrin releasing peptide-like activity having the structures Ala-Pro-Val-Ser-Val-Gly-Gly-Gly-Thr-Val-Leu-Ala-Lys-Met-Tyr-Pro-NH.sub.2 and Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH.sub.2, have been isolated from rat and guinea pig brain extracts and synthesized by a solid phase peptide synthesis methods. The GRP-like peptides are useful as pharmaceuticals to lower body temperature, increase respiratory activity, reduce food intake, stimulate pancreatic hormone release, stimulate pituitary hormone release and suppress thyroid hormone release in mammals.
    Type: Grant
    Filed: April 19, 1984
    Date of Patent: September 23, 1986
    Assignee: Board of Trustees of the Leland Stanford Junior University
    Inventors: Jack D. Barchas, Eckard Weber, Christopher J. Evans, Jaw-Kang Chang, Robin G. Lorenz, Kevin A. Roth
  • Patent number: 4562175
    Abstract: A synthetic peptide growth hormone releasing factor having substantially the following amino acid sequence: ##STR1## methods of inducing growth in an animal and growth inducing pharmaceutical compositions, including animal feed compositions, are disclosed.
    Type: Grant
    Filed: February 3, 1984
    Date of Patent: December 31, 1985
    Inventors: Ding Chang, Akira Arimura, Michael D. Culler, Jaw-Kang Chang